Mullen JO, Mullen NL (1992) Hip fracture mortality A prospective

Mullen JO, Mullen NL (1992) Hip fracture mortality. A prospective, multifactorial study to predict and minimize death risk. Clin Orthop Relat Res 280:214–22PubMed 30. Nightingale S, Holmes J, Mason J, House A (2001) Psychiatric illness and mortality

after hip fracture. Lancet 357:1264–1265CrossRefPubMed 31. Inouye SK (1994) The dilemma of delirium: clinical and research controversies regarding diagnosis and evaluation of delirium in hospitalized elderly medical patients. Am J Med 97:278–288CrossRefPubMed 32. Blacker DJ, Flemming KD, Link MJ, Brown RD Jr (2004) The preoperative cerebrovascular Fedratinib in vivo consultation: common cerebrovascular questions before general or cardiac surgery. Mayo Clin Proc 79:223–229CrossRefPubMed”
“Introduction A history of non-vertebral fracture (NVF) is associated with a doubling of the risk of a subsequent fracture, and the subsequent fracture risk is quadrupled after a vertebral fracture [1, 2]. This subsequent fracture risk is not constant over time and is driven by the high, three to fivefold increase in the years immediately after a first fracture, followed by a gradual waning off later on [3]. This has been shown for

repeat morphometric vertebral fractures [4], subsequent clinical spine, forearm and hip fractures in patients who were hospitalised with a vertebral fracture [5], repeat low-trauma fractures in subjects older than 60 years [6], repeat clinical vertebral and non-vertebral fractures from menopause onwards [3, 7, 8] and repeat hip fractures [9]. As a result, it has been shown in long-term follow-up studies that 40% isometheptene to 50% of HDAC inhibitors list all subsequent fractures occur within 3 to 5 years after a first fracture. The clinical implication is that patients older than 50 years presenting with a fracture need immediate attention to reduce reversible risk factors of a subsequent fracture. This indicates that to undertake immediate care in fracture patients is necessary, such as the Fracture Liaison Service, the involvement of a fracture nurse and other initiatives in the field of post-fracture

care [10–13]. It also indicates that treatment, which has been shown to reduce fracture risk within short term, should be started as soon as possible in patients with a high fracture risk [14]. An increased risk of Akt inhibitors in clinical trials mortality has been documented after hip, vertebral and several non-hip, non-vertebral fractures [15]. Similar to subsequent fracture risk, this increase in mortality is higher immediately after fracture than later on. In women and men older than 60 years, nearly 90% of excess deaths related to fracture over the 18 years of observation occurred in the first 5 years. Of the 5-year post-fracture excess mortality, approximately one third of deaths were associated to hip, vertebral and non-hip, non-vertebral fractures, respectively. The major causes of death were related to cardiovascular and respiratory comorbidity and infections [15].

Comments are closed.